| Followers | 238 |
| Posts | 15504 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Sunday, April 02, 2017 12:07:20 PM
I agree ex. Yonemura primarily deals with LP and the MFN clause. There is really no mention of Adam or Buzdar or P5 in these other two cases.
Perhaps those arguing for the Yonemura and the Tharp/Henkel cases think they played some sort of role in LP doing away with that MFN clause, and feel then that they are entitled to having at least their fees covered. Whether we'll see any money returned to NWBO is doubtful, but I guess possible. I'll be honest, I doubt the lawyers are arguing for that to be the case at all, but we'll see.
We all know that the reason the MFN clause was removed was to stay on NASDAQ and really had nothing to do with the lawsuit. But I'm sure a persistent lawyer for these cases would argue otherwise.
Therefore, in the interests of putting these lawsuits behind them, the company would most likely simply use their insurance to cover the legal fees of those lawyers, and be done with them.
Perhaps those arguing for the Yonemura and the Tharp/Henkel cases think they played some sort of role in LP doing away with that MFN clause, and feel then that they are entitled to having at least their fees covered. Whether we'll see any money returned to NWBO is doubtful, but I guess possible. I'll be honest, I doubt the lawyers are arguing for that to be the case at all, but we'll see.
We all know that the reason the MFN clause was removed was to stay on NASDAQ and really had nothing to do with the lawsuit. But I'm sure a persistent lawyer for these cases would argue otherwise.
Therefore, in the interests of putting these lawsuits behind them, the company would most likely simply use their insurance to cover the legal fees of those lawyers, and be done with them.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
